Cerevel's GABA A modulator reduces photosensitivity in epilepsy patients

After spinning out of Pfizer in October to develop the pharma's discontinued neuroscience pipeline, Cerevel plans to begin by year end another Phase II trial of CVL-865 in broader epilepsy populations.

Cerevel Therapeutics LLC (Boston, Mass.) announced the next trial as data published in Neurology showed that CVL-865 significantly reduced photosensitivity in a Phase IIa trial to treat patients with photosensitive epilepsy. CVL-865 (formerly PF-06372865) is a GABA A receptor α 2 (GABRA2), GABRA3 and GABRA5 positive allosteric modulator...